Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (porphyrin) preparation presented as a sterile intravenous solution for intravenous use. It is employed to treat acute intermittent porphyria attacks by supplying exogenous heme to patients experiencing metabolic crises.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality and regulatory conformity across markets. The company manages cold‑chain logistics and provides comprehensive documentation to meet import requirements. Clients benefit from responsive technical support and timely delivery.

Normosang is used in the management of acute porphyria disorders by providing heme to suppress the overproduction of toxic precursors. - Acute intermittent porphyria (AIP) attacks: reduces accumulation of aminolevulinic acid and porphobilinogen, helping to alleviate neurovisceral symptoms. - Acute hepatic porphyria: restores heme pool, decreasing hepatic ALA synthase activity and mitigating crisis severity. - Drug‑induced porphyria exacerbations: counteracts porphyrinogenic drug effects by supplying exogenous heme, facilitating metabolic control.

Normosang may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion site pain or erythema: mild discomfort at the injection site. - Nausea or vomiting: transient gastrointestinal upset. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hypotension: sudden drop in blood pressure requiring monitoring. - Anaphylactic reaction: severe allergic response with respiratory compromise. - Hemolysis: destruction of red blood cells leading to anemia.

When using Normosang, clinicians should observe several precautionary measures to ensure patient safety. - Hepatic monitoring: assess liver function tests before and during therapy. - Renal monitoring: evaluate kidney function, especially in patients with pre‑existing impairment. - Hypersensitivity assessment: avoid use in individuals with known allergy to hemin or formulation components. - Pregnancy consideration: use only if the potential benefit outweighs risk, as safety data are limited. - Dosage oversight: ensure the prescribed dose is administered by qualified healthcare professionals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Porphyrinogenic drugs (e.g., barbiturates, sulfonamides, antiepileptics): may exacerbate porphyria and reduce treatment benefit. - Anticoagulants (e.g., warfarin): hemin can alter coagulation parameters, increasing bleeding risk. - Iron supplements: excess iron may interfere with heme metabolism.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin): may affect hemin clearance. - Vitamin D analogues: potential additive effect on calcium metabolism. - Other intravenous solutions: ensure compatibility to prevent precipitation.